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TO transmit  the  information  inside  the  cell,  one
possibility  is the  action of an enzyme called kinase
that  phosphorylates  other  proteins.  To  study  these
enzymes, chemical compound synthesis was needed
to know the function and the mechanism of activa-
tion.  The  major  difficulty  is  creating  a  specific
molecule  for  one  kinase. In  this  study,  we test  the
action  of  Rho-kinase  inhibitors  (HA-1077  and
Y-32885) on protein kinase C (PKC) in the respiratory
burst in the human polymorphonuclear neutrophils.
We have shown that these compounds could inhibit
the  anion  superoxide  production.  To  prove  their
action on PKC, we have shown a decrease of binding
of  a  specific  ligand  (phorbol-12,13-dibutyrate)  with
each inhibitor. During its activation, PKC was trans-
located from the cytoplasm to the plasmic membrane.
We have also shown an inhibition of this transloca-
tion, proving an inhibition of PKC by  HA-1077  and
Y-32885.
Key words:  Protein  kinase  C, Translocation,  Antioxidant
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Aims
In the signal transduction system there is an enzyme
that plays an important part, more particularly by its
presence in most cellular types and by the number of
pathway networks to which it belongs. This enzyme is
protein kinase C (PKC), discovered by Nishizuka et
al.1 PKC is a serine/threonine kinase, meaning that it
is  able  to  phosphorylate  proteins  on  serine  or  on
threonine  residues,  thus  implicating  its  activation,
which leads to cellular response. PKC exists in several
isoforms divided into three subclasses: classical PKC
(PKCa,  PKCbI,  PKCbII,  PKCg),  novel  PKC  (PKCd,
PKC«, PKCh, PKCu), and atypical PKC (PKCz, PKCl)
that, added to other proteins, creates a new family
known as the PKC-related kinases (PKCm). Classical
PKC can be stimulated by calcium, various lipids like
diacylglycerol  or  phosphatidylserine,  or  analogues
like phorbol esters. Novel PKC can be activated by
diacylglycerol  and  phosphatidylserine  but  not  by
calcium.  Stimulation  of  the  atypical  PKC  is  also
discussed, and most studies have shown that activa-
tion is independent of calcium or diacylglycerol and
its  analogue,2 whereas  some  results  conclude  that
phorbol  esters  can  stimulate  these  enzymes.3 One
PKC-related kinase, the isoform PKCm, is dependent
on  the  stimulation  of  phosphatidylserine, diacylgly-
cerol and their analogues.4 As for other PKC-related
kinases, their stimulation is independent of calcium
or  diacylglycerol  or  phorbol  esters,  and  they  are
sensitive  to  acid  phospholipids  like  phosphatidyl
inositol-4,5-biphosphate  and  phosphatidylinositol-
3,4,5-triphosphate.5
There  are  also  other  parameters  influencing  the
potential activity of PKC. The first is the presence of
phosphorylations on specific sites on the protein that
can be phosphorylated. These phosphorylations influ-
ence the tridimensional structure of the enzyme, by
acting  on  the  affinity  of  diverse  factors  such  as
diacylglycerol,  calcium  or chemical compound, the
capacity of the enzyme to be activated, its stability
and  its potential to bind other proteins.6,7 Another
parameter is binding with anchoring proteins, which
can regulate the activity of the PKC according to its
cellular localisation. When PKC is unstimulated, the
enzyme is bound to a kinase anchoring protein and is
localised in the cytoplasm. As a result of the stimula-
tion by factors already described, PKC is translocated
by shuttle protein to the plasmic membrane where
the  enzyme  binds  with  the  protein  receptor  for
activated C kinase; at this point, the PKC attains its
enzymatic capacity.8,9
The kinase family is regularly studied because of its
implication in many cellular processes and transduc-
tion  signals.10 One  aspect  of  these  studies  is  the
research of  compounds  capable  of  inhibiting  or  of
regulating the activity of kinases. We test two chem-
ical products. HA-1077, or 1–5-(isoquinoline sulfonyl)-
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pressor  of  the  vascular  contraction  by  action  on
different enzymes as PKC, myosin light chain kinase
or  Rho-kinase.11,12 Y-32885,  or  (R)-(+)-N-(4-pyridyl)-
4-(–1-aminoethyl)-benzamide, is an inhibitor of Rho-
kinase to regulate the phosphorylation of myosin light
chain and to inhibit the smooth muscle contraction,
or  to  inhibit  the  lysophosphatidic  acid  induced
growth cone collapse.13,14
In  the  present  study,  we  chose  to  take  into
consideration the implication of the PKC on oxidative
stress  in  human  neutrophils.  Cells  were  separated
from other blood constituents using a rapid density
gradient  technique.15 To  check  whether  the  com-
pounds  had  an  action  on  the  stress  oxidative,  we
measured  the  variation  of  superoxide  anion  (O2
·–)
produced. The  activators  were  N-formyl-methionyl-
leucyl-phenylalanine (fMLP) and the phorbol-12-myr-
istate-13  acetate  (PMA).  The  former  is  a  peptide
mimicking a natural ligand with membrane receptors
to obtain stimulation of the cells, proceeding by the
classical transduction pathways,16 whereas the latter
is  a  chemical  compound  capable  of  activating  the
polymorphonuclear by action on the PKC and capa-
ble of inducing a lengthy cell response.17 To check
whether the compounds had an action on PKC, we
first purified PKC from the cellular suspension and
then  measured  binding  variation  between  a  radio-
active phorbol ester and PKC. To confirm this result,
we visualised the translocation or inhibition  of  the




Buffer  compounds  and  chemical  products  were
purchased from Sigma Chemical Co. (St Louis, MO,
USA). The  chromatography  column  was  purchased
from  Pharmacia Biotech AB (Uppsala,  Sweden). Pri-
mary and secondary antibodies were purchased from
Tebu  (Le  Perray  en Yvelines,  France).  ECL Western
blotting detection reagents and Hyperfilm ECL were
purchased from Amersham International plc. (Amer-
sham, Buckinghamshire, UK).
Cell separation technique
The 15ml of fresh drawn human heparinised blood
obtained from healthy donor was diluted 1: 2 with a
0.1M phosphate buffer saline (pH 7.4). Then 10ml of
histopaque®-1077  was  placed  at  the  bottom  of  a
conical tube. After centrifugation (400 ´ g for 30min
at  20°C),  10ml  of  plasma  were  put  aside,  the
supernatant  was  eliminated,  the  pellet  was  resus-
pended  with  the  plasma,  and  the  suspension  was
diluted 1:  10  with an ammonium  chloride solution
(0.15M  ammonium  chloride,  10 mM  sodium  bicar-
bonate; pH 7.4). After beginning the haemolysis, the
tube was conserved at 4°C and gently shaken all the
time. The  polymorphonuclears  were  recovered  by
centrifugation (400 ´ g for 10min at 4°C), and then
the cells  were washed twice.15 Cell viability, deter-
mined by blue Trypan exclusion, was over 95%. The
cells were kept at 4°C until use.
Assessment of the cytotoxicity of the
compound
The  cytotoxicity  of  the  inhibitor  was  estimated by
dosing lactate dehydrogenase activity in the cellular
supernatant  of  a  polymorphonuclear  suspension.
Then  5.106 GrN  were  incubated  in  1ml  of  Hank’s
Hepes buffer at 37°C with several concentrations of
the compound. The suspension was centrifuged (400
´ g for  10min  at  4°C),  all  supernatants  were
separated, and the pellet of the reference tube was
resuspended with 1ml of water and shaken for 5min
to lyse the cells. This tube was centrifuged (400 ´ g for
10min  at 4°C), and the supernatant was also sepa-
rated. The enzymatic activity of lactate dehydrogenase
was measured at 30°C by enzymatic kinetic read at
340nm  after  adding  0.2 mM  NADH  and  1.6 mM
pyruvate, as described in  the manufacturer’s proto-
col.18 The  percentage  of  lactate  dehydrogenase
released  was  estimated  in  comparison  with  the
maximal activity of this enzyme.
Anion superoxide assay
The polymorphonuclears (5.106 GrN/ml) were incu-
bated with the inhibitor, and cells were activated with
160nM PMA or 1mM fMLP at 37°C. After incubation,
0.2mg/ml  of  ferricytochrome  C  was  added to  the
cellular suspension, and this compound was reduced,
causing a change in colour measured at 550nm. The
concentration  of  anion  superoxide  was  calculated
with  the  extinction  coefficient  E550 nm =  2.1  ´
10–2 mM–1 cm–1 as previously described.19
An  acellular  model  was  used  to  determine  a
scavenger effect. Anion superoxide was produced by
a  hypoxanthine-xanthine  oxidase  system.20 Absor-
bance was measured at 550nm.
Purification of the PKC by chromatography
A total of 25.106 polymorphonuclears at 5.106 GrN/ml
were  incubated  with  phenylmethylsulfonyl  fluoride
(PMSF) at 57mM for 15min at 4°C. The suspension
was centrifuged (400 ´ g for 10min at 4°C), and the
pellet  was  resuspended  by  a  lysate  buffer  (20 mM
TRIS, 0.33 mM EGTA, 2 mM EDTA, 0.33 mM sucrose,
0.5mg/ml leupeptin, 0.30mg/ml PMSF, 50 mM b-mer-
captoethanol;  pH  7.5)  at  50.106 GrN/ml. The  cells
were lysed by sonication six times for 5sec, taking
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centrifuged  (100,000  ´ g for  30min  at  4°C),  the
supernatant was mixed volume/volume with DEAE-
Sephacel, and the suspension was shaken for 1h at
4°C. The mixture was then put into the column and
washed with 10ml of lysate buffer, and the elution of
PKC was obtained by adding 150 mM sodium chlo-
ride.21 Then, 57mM PMSF was added to the purified
protein and kept at –80°C until use.
Binding
Twenty micrograms of purified protein were used per
tube, the compound was incubated with the enzyme
for 15min at 30°C in a specific buffer (20 mM TRIS,
100 mM  potassium  chloride,  0.5 mM  calcium  chlo-
ride,  50mg/ml  phosphatidylserine,  0.17%  dimethyl-
sulfoxide (DMSO), 0.2% ethanol; pH 7.5),  and then
30 mM  [3H]phorbol-12,13-dibutyrate  (activity,
18.6Ci/mmol) was placed in each tube to start the
reaction; the final  volume  was 325ml. The mixture
was put at 30°C for 10min, and the reaction stopped
by adding 1ml of freezing 0.5% DMSO solution. The
tube  was  emptied  on  a  GF/C  filter,  before  being
plunged  in  a  0.3%  polyethylenimine  solution. The
filter was washed five times with the DMSO solution,
and dried by aspiration.22 Residual radioactivity was
measured  with  a  scintillation  counter.  Non-specific
binding  was  determined  by  cold  phorbol-
12,13-dibutyrate.
Preparation of cells for Western blot
A total of 5.106 cells/ml were incubated for 20min
with  the  57mM  PMSF  at  4°C  and  then  were  cen-
trifuged (400 ´ g for 10min at 4°C) to eliminate the
PMSF solution. They were resuspended in a Hank’s
Hepes  buffer  (pH  7.4),  then  incubated  with  the
inhibitor  at  37°C,  and  activation  was  started  by
160nM  phorbol-12-myrystate-13-acetate  at  37°C  for
5min  or  1mM  fMLP  at  37°C  for  10min. The  final
volume was 5ml. Stimulation was stopped by adding
of  20ml  of  ice-cold  Hank’s  Hepes  buffer  and  cen-
trifuged (400 ´ g for 10min at 4°C). The pellet was
resuspended in 500ml of buffer (20 mM TRIS, 5 mM
EGTA,  2 mM  EDTA,  50 mM  b-mercaptoethanol,
1 mM  PMSF,  330mM  leupeptin,  350mM  antipain,
350mM pepsatin, 40mM chymostatin, 3.1mM aproti-
nin,  0.25 mM  sucrose;  pH  7.5)  and  sonicated  six
times  for  5sec. The  lysate  protein  was  centrifuged
(100,000  ´ g for  30min  at  4°C). The  supernatant
was kept, the pellet was resuspended with 200ml of
the  previous  buffer,  and  each  sample  was  mixed
with a sodium dodecyl sulf.ate (SDS) sample buffer
(32 mM  TRIS,  71 mM  SDS,  1.35 mM  glycerol,
0.76 mM  bromophenol  blue)  and  boiled  for
10min.23 The protein concentration was determined
by Folin assay.
Western blot
The equivalent of 130mg of protein was analysed by
polyacrylamide gel  electrophoresis on 10%  SDS  for
15h at 40mA. The proteins were electrophoretically
transferred to the nitrocellulose membrane for 2h at
36V. The membrane was saturated with a solution of
10%  fat-free  dried  milk  in TRIS  buffer  saline-0.05%
Tween 20  (TBS-Tween  20)  for  30min,  followed  by
incubation  with  rabbit  polyclonal  antibodies  (anti-
PKCbI,  anti-PKCbII  or anti-PKCz (1/1000  dilution))
for 1.5h  at room  temperature. The membrane was
washed  twice  for  10min  with TBS-Tween  20,  fol-
lowed  by  incubation  with  (1/10,000)  dilution  of  a
rabbit peroxidase-conjugated secondary antibody for
45min  at  room  temperature.  The  membrane  was
abundantly  washed  with  TBS-Tween  20  and  then
incubated with an ECL mixture of two reagents for
20min,  and  the  films  were  developed  in  a  dark
room.
Statistical studies
The  data  obtained  were  subjected  to  statistical
analysis using a non-parametric test (Student’s t-test),
where p < 0.05 was considered significantly different
versus reference.
Results
Activation of the PKC
First  at  all,  it  was  necessary  to  determine  the
conditions of time and concentration to activate PKC.
This  was  carried  out  using  the  property  of  this
enzyme to be translocated from the cytoplasm to the
plasmic membrane during the time of its activation,
by Western blot after separation of the cytoplamic and
membrane fraction. With both activators (fMLP and
PMA), we noted the three isoforms (PKCbI, PKCbII
and PKCz) of the PKC in the cytoplasmic part when
the  polymorphonuclears  were  unstimulated  and
when  these  isoenzymes  were  located  in  the  mem-
brane part after the stimulation of the cells by 160nM




To confirm a possible effect of the compounds on the
production of O2
·–, it had to be checked that these
molecules did not change the biological properties of
the polymorphonuclears. The absence of cytotoxicity
(< 5%) was controlled in HA-1077 and in Y-32885 for
concentrations  between  5 ´ 10–3 and  1  ´ 10–7 M
under  the  conditions  previously  described:  1mM
fMLP for 10min and 160nM PMA for 5min.
It was also necessary to check that the compounds
did not interact with the O2
·– produced (< 5%). The
PKC translocation in human neutrophils
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were  not  oxygen  radical  scavengers  for  concentra-
tions between 5 ´ 10–3 and 1 ´ 10–7 M.
Human  polymorphonuclears  stimulated  with
160nM PMA for 5min or 1mM fMLP for 10min were
able to release a large quantity of O2
·–. After incuba-
tion  with  the  inhibitors,  the  O2
·– production
decreased in a concentration-dependent manner, to
be totally inhibited. The IC50 values calculated for the
HA-1077 were 1.18 ´ 10–4 ± 0.21 ´ 10–4 M for PMA
activation and 4.36 ´ 10–4 ± 0.16 ´ 10–4 M for fMLP
activation (Fig. 2A). The IC50 values calculated for the
Y-32885 were 0.79 ´ 10–4 ± 0.14 ´ 10–4 M for PMA
activation and 1.99 ´ 10–4 ± 0.08 ´ 10–4 M for fMLP
activation (Fig. 2B).
Binding
To  demonstrate  that  HA-1077  and  Y-32885  were
implicated in the inhibition of the oxidative burst in
the human polymorphonuclear, we studied the bind-
ing of these compounds with the purified PKC. For
this  binding,  a  phorbol  ester  was  used:  phorbol-
12,13-dibutyrate, which is a specific ligand for PKC.
After  incubation  of  15min  incubation  with  the
protein, phorbol ester was added to the sample and
the  binding  variation was  measured  and compared
with the sample without inhibitor. The IC50 values of
the binding were 0.789 ´ 10–6 ± 0.024 ´ 10–6 M with
Y-32885 and 1.317 ´ 10–6 ± 0.057 ´ 10–6 M with HA-
1077, and the decreases in binding were dependent
on concentration (Fig. 3).
Inhibition of the translocation of the PKC
Visualisation of the presence or absence of transloca-
tion was followed by Western blot. The stimulation
was carried out by  160nM PMA for  5min or 1mM
fMLP for 10min. Two concentrations of HA-1077 and
Y-32885  were  used,  0.5  and  10 mM,  to  show  the
influence of these compounds on PKC.
For the three isoforms of PKC (PKCbI, PKCbII and
PKCz), its translocation was confirmed during stim-
ulation whatever the activators used, either fMLP or
PMA. For a weak concentration (0.5 mM) of HA-1077
or Y-32885, translocation from the cytoplasm to the
plasmic  membrane  was  also  shown  but,  on  the
contrary,  with  a  high  concentration  of  inhibitors
(10 mM), no difference was noted in localisation of
the  three  isoenzymes  during  the  same  time  of
incubation (Fig. 4).
Conclusions
PKC is  involved  in  activating other proteins  in  the
pathway  network,  by  phosphorylating  to  facilitate
their  cellular  response.24 This  system  of  control  is
diffused  in  the  organism,  and  explains  the  broad
distribution of this enzyme and its biological impor-
tance.25 We have shown a cellular action of HA-1077
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FIG. 1. For the reference, cells were incubated for the same length of time for each activator, then cytoplasm (lane 1) and
plasmic membrane (lane 2) were separated by centrifugation. For the activated cells, stimulation was made by 160nM PMA for
5min or by 1mM fMLP for 10min. After centrifugation, the cytoplasm (lane 3) was separated from the plasmic membrane (lane
4). Results are representative of three experiments.and Y-32885 on the superoxide anion production in
the human polymorphonuclear neutrophils. This pro-
duction was inhibited, and the IC50 values calculated
for the HA-1077 were 1.18 ´ 10–4 ±0.21 ´ 10–4 M for
PMA activation and 4.36 ´ 10–4 ± 0.16 ´ 10–4 M for
activation  by  the  fMLP.  For  the Y-32885,  the  IC50
values calculated were 0.79 ´ 10–4 ± 0.14 ´ 10–4 M for
PMA activation and 1.99 ´ 10–4 ± 0.08 ´ 10–4 M for
fMLP  activation. These  results  prove  that  the  two
compounds can have an action on the inflammatory
processes  implicating  the  reactive  oxygen  species,
but it is important to know how HA-1077 and Y-32885
decrease  the  quantity  of  superoxide  anion.  The
reactive  oxygen  species  were  produced  by  an
enzyme: the NADPH oxidase.26 Recent studies have
shown  that  PKC  has  an  important  role  for  the
activation  of  the  NADPH  oxidase.27 So,  we  have
verified  that  HA-1077  and Y-32885  can  inhibit  the
superoxide production by acting towards PKC.
The first element proving that the inhibition of the
oxidative burst was due to an action of chelerythrine
chloride  on  PKC  was  decreased  binding  with  a
compound having a highly affinity for this enzyme.28
The chosen ligand was the phorbol-12,13-dibutyrate.
The  first  step was to  partially  purify  PKC to avoid
binding  with  other  proteins.  The  study  revealed
decreased recognition of the protein to phorbol ester.
The IC50 values calculated were 0.789 ´ 10–6 ± 0.024
´ 10–6 M  for Y-32885  and  1.317 ´ 10–6 ±  0.057 ´
10–6 M for HA-1077, but are insufficient to prove that
PKC  is  inhibited  because  phorbol  esters  can  bind
with  other  proteins  leading  to  superoxide  anion
PKC translocation in human neutrophils
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FIG. 2. Action of HA-1077 (A) and Y-32885 (B) on the superoxide production by the human polymorphonuclear. The cells were
incubated with various concentrations of the compound for 15min at 37°C. Stimulation was then started by 160nM PMA for
5min or 1mM fMLP for 10min at 37°C. Cytochrome C was added to the samples to measure the superoxide produced. Results
are the mean ± SEM of six experiments. Significant difference versus the reference was evaluated by Student’s t-test, p <
0.05.production as Ras-GRP and UNC-13.29 Moreover, the
difference between the values for the inhibition of the
superoxide anion production and the values for the
inhibition  binding  is easily explainable. The former
takes  the  crossing  of  membranes  into  account
whereas  the  latter  measures  directly  an  action  of
compounds on PKC, hence lower values.
It was necessary to develop a further strategy to
assign the decrease in respiratory burst to inhibition
of  PKC. The  PKC  has  to  be  translocated from  the
cytoplasm  to  the  plasmic  membrane  during  its
activation.30This was confirmed using fMLP and PMA
as activators; the three isoforms (PKCbI, PKCbII and
PKCz) were translocated with 1mM fMLP for 10min
and 160nM PMA for 5min. For the isoenzymes PKCbI
and PKCbII, first results confirm other studies about
classical PKC,31 but activation of the isoform PKCz by
PMA is a controversial point. Several publications had
shown that the isoform PKCz cannot be translocated
to the plasmic membrane, but a lot of research has
reached the same conclusions as us.3,32This result can
be explained by the presence of a cystein-rich domain
on this isoform that could be implicated in binding
with concentrated phorbol esters. Another explana-
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FIG. 3. Action of HA-1077 and Y-32885 on the binding of phorbol-12,13-dibutyrate with PKC. The proteins were incubated with
the compounds  at  30°C  for  10min.  Phorbol  ester  was then  added to  the  samples  for  15min  at  30°C,  and  the residual
radioactivity was measured by a scintillation counter. Non-specific binding was determined by cold phorbol-12,13-dibutyrate.
Results are the mean ± SEM of six experiments. Significant difference versus the reference was evaluated by Student’s t-test,
p < 0.05.
FIG. 4. Action of HA-1077 and Y-32885 on the translocation of PKC. The cells were incubated with the compounds for 15min
with different concentrations (0.5 and 10 mM), and the polymorphonuclears were activated by 160nM PMA for 5min at 37°C
or by 1mM fMLP for 10min at 37°C. Lane 1, Cytoplasm of incubated cells with 10 mM HA-1077; lane 2, membrane of incubated
cells with 10 mM HA-1077; lane 3, cytoplasm of incubated cells with 0.5 mM HA-1077; lane 4, membrane of incubated cells with
0.5 mM HA-1077; lane 5, cytoplasm of incubated cells with 10 mM Y-32885; lane 6, membrane of incubated cells with 10 mM
Y-32885; lane 7, cytoplasm of incubated cells with 0.5 mM Y-32885; lane 8, membrane of incubated cells with 0.5 mM Y-32885.
Results are representative of three experiments.tion may  be  the involvement  of  other pathways. A
recent  study  shows  that  one  isoform  of  PKC  can
phosphorylate, and therefore activate, another PKC in
unchanged cells. As our model uses unchanged blood
cells, we have conserved the transduction pathway,
contrary  to  other  studies  using  changed  cells.29 If
inhibition  of  this  translocation could  be  shown,  it
would  also  prove  the  inhibition  of  PKC,  which  is
correlated with the antioxidant properties of HA-1077
and Y-32885. Having already defined the conditions to
visualise the translocation of PKC from cytoplasm to
plasmic  membrane,  they  were  again  applied,  i.e.
160nM PMA for 5min or 1m fMLP for 10min. For a
weak concentration (0.5 mM) in inhibitors, transloca-
tion  to  the  plasmic  membrane  was  maintained;
whereas  for  a  high  concentration  in  compounds
(10 mM), translocation to the plasmic membrane was
totally inhibited. In addition, these experiments may
involve some specific action of HA-1077 and Y-32885
towards one PKC isoform.
In this study, we have proved the inhibition action
of  HA-1077  and  Y-32885  on  respiratory  burst  in
human polymorphonuclears. Usually used to research
about Rho-kinase, they can also inhibit PKC. Another
molecule of the same family of HA-1077, the H7, has
a low selectivity for one kinase. The IC50 value, in a
model using isolated enzyme, for PKC is 1.8mM, for
protein kinase A it is 1.6mM and for the phosphor-
ylase kinase it is 6.5mM.33 This can be explained by
the  action  mode  of  these  family  compounds:  they
bind the ATP site of the enzyme but this part of the
protein is highly conserving,34 making it difficult to
have  good  selectivity  for  one  kinase.  It  must  be
important to develop compounds with better speci-
ficity for one kinase family to study them and to have
lead compounds for therapeutic application.
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